Literature DB >> 24778352

MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy.

Tze Yee Lim1, R Jason Stafford, Rajat J Kudchadker, Madhuri Sankaranarayanapillai, Geoffrey Ibbott, Arvind Rao, Karen S Martirosyan, Steven J Frank.   

Abstract

Brachytherapy, a radiotherapy technique for treating prostate cancer, involves the implantation of numerous radioactive seeds into the prostate. While the implanted seeds can be easily identified on a computed tomography image, distinguishing the prostate and surrounding soft tissues is not as straightforward. Magnetic resonance imaging (MRI) offers superior anatomical delineation, but the seeds appear as dark voids and are difficult to identify, thus creating a conundrum. Cobalt dichloride-N-acetyl-cysteine (C4) has previously been shown to be promising as an encapsulated contrast agent marker. We performed spin-lattice relaxation time (T1) and spin-spin relaxation time (T2) measurements of C4 solutions with varying cobalt dichloride concentrations to determine the corresponding relaxivities, r1 and r2. These relaxation parameters were investigated at different field strengths, temperatures and orientations. T1 measurements obtained at 1.5 and 3.0 T, as well as at room and body temperature, showed that r1 is field-independent and temperature-independent. Conversely, the T2 values at 3.0 T were shorter than at 1.5 T, while the T2 values at body temperature were slightly higher than at room temperature. By examining the relaxivities with the C4 vials aligned in three different planes, we found no orientation-dependence. With these relaxation characteristics, we aim to develop pulse sequences that will enhance the C4 signal against prostatic stroma. Ultimately, the use of C4 as a positive contrast agent marker will encourage the use of MRI to obtain an accurate representation of the radiation dose delivered to the prostate and surrounding normal anatomical structures.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24778352      PMCID: PMC4090919          DOI: 10.1088/0031-9155/59/10/2505

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  11 in total

1.  MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results.

Authors:  Cedric M J de Bazelaire; Guillaume D Duhamel; Neil M Rofsky; David C Alsop
Journal:  Radiology       Date:  2004-03       Impact factor: 11.105

2.  T1/T2*-weighted MRI provides clinically relevant pseudo-CT density data for the pelvic bones in MRI-only based radiotherapy treatment planning.

Authors:  Mika Kapanen; Mikko Tenhunen
Journal:  Acta Oncol       Date:  2012-06-19       Impact factor: 4.089

3.  Positive contrast MRI of prostate brachytherapy seeds based on resonant frequency offset mapping.

Authors:  Gregory Whitehead; Jim Ji
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2010

4.  Dosimetric influence of seed spacers and end-weld thickness for permanent prostate brachytherapy.

Authors:  Christopher S Melhus; Justin K Mikell; Steven J Frank; Firas Mourtada; Mark J Rivard
Journal:  Brachytherapy       Date:  2013-10-16       Impact factor: 2.362

5.  1H T1 and T2 measurements of the MR imaging contrast agents Gd-DTPA and Gd-DTPA BMA at 1.5T.

Authors:  J R Reichenbach; T Hackländer; T Harth; M Hofer; M Rassek; U Mödder
Journal:  Eur Radiol       Date:  1997       Impact factor: 5.315

6.  MRI of prostate brachytherapy seeds at high field: a study in phantom.

Authors:  S D Thomas; K Wachowicz; B G Fallone
Journal:  Med Phys       Date:  2009-11       Impact factor: 4.071

Review 7.  MRI contrast agents: basic chemistry and safety.

Authors:  Dapeng Hao; Tao Ai; Frank Goerner; Xuemei Hu; Val M Runge; Michael Tweedle
Journal:  J Magn Reson Imaging       Date:  2012-11       Impact factor: 4.813

8.  A biodistribution and toxicity study of cobalt dichloride-N-acetyl cysteine in an implantable MRI marker for prostate cancer treatment.

Authors:  Steven J Frank; Mary J Johansen; Karen S Martirosyan; Mihai Gagea; Carolyn S Van Pelt; Agatha Borne; Yudith Carmazzi; Timothy Madden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-22       Impact factor: 7.038

9.  A novel MRI marker for prostate brachytherapy.

Authors:  Steven J Frank; R Jason Stafford; James A Bankson; Chun Li; David A Swanson; Rajat J Kudchadker; Karen S Martirosyan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  6 in total

1.  Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers.

Authors:  Geoffrey V Martin; Thomas J Pugh; Usama Mahmood; Rajat J Kudchadker; Jihong Wang; Teresa L Bruno; Tharakeswara Bathala; Pierre Blanchard; Steven J Frank
Journal:  Brachytherapy       Date:  2017-05-10       Impact factor: 2.362

2.  Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy.

Authors:  Jingfei Ma; Marinus A Moerland; Aradhana M Venkatesan; Tharakeswara K Bathala; Rajat J Kudchadker; Kristy K Brock; Steven J Frank
Journal:  Brachytherapy       Date:  2017-01-04       Impact factor: 2.362

3.  Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI markers for MRI-based prostate postimplant assessment.

Authors:  Tze Yee Lim; Rajat J Kudchadker; Jihong Wang; R Jason Stafford; Christopher MacLellan; Arvind Rao; Geoffrey S Ibbott; Steven J Frank
Journal:  Med Phys       Date:  2016-07       Impact factor: 4.071

4.  Fully Balanced SSFP Without an Endorectal Coil for Postimplant QA of MRI-Assisted Radiosurgery (MARS) of Prostate Cancer: A Prospective Study.

Authors:  Jeremiah W Sanders; Aradhana M Venkatesan; Chad A Levitt; Tharakeswara Bathala; Rajat J Kudchadker; Chad Tang; Teresa L Bruno; Christine Starks; Edwin Santiago; Michelle Wells; Carl P Weaver; Jingfei Ma; Steven J Frank
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-09-24       Impact factor: 7.038

Review 5.  Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers.

Authors:  Alexandru Mihai Nicolae; Niranjan Venugopal; Ananth Ravi
Journal:  Cancer Nanotechnol       Date:  2016-07-04

6.  Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience.

Authors:  Tze Yee Lim; Rajat J Kudchadker; Jihong Wang; Tharakeswara Bathala; Janio Szklaruk; Thomas J Pugh; Usama Mahmood; Geoffrey S Ibbott; Steven J Frank
Journal:  J Contemp Brachytherapy       Date:  2016-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.